These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 28809079)

  • 21. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia.
    Ferrajoli A; Buzdar AU; Dejesus Y; Cheng L; Michaud LB; Rodriguez MA
    Cancer; 2011 Jul; 117(14):3268-75. PubMed ID: 21264831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
    Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
    Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.
    Stroupe KT; Tarlov E; Lee TA; Weichle TW; Zhang QL; Michaelis LC; Ozer H; Durazo-Arvizu R; Browning MM; Hynes DM
    Pharmacotherapy; 2012 Nov; 32(11):988-97. PubMed ID: 23108695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
    Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
    Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
    Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
    Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
    Thavarajah S; Choi MJ
    Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy.
    Boone JD; Fauci JM; Walters CL; Whitworth JM; Bevis KS; Alvarez RD
    Int J Gynecol Cancer; 2013 Feb; 23(2):367-71. PubMed ID: 23266649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. End of an era for erythropoiesis-stimulating agents in oncology.
    Schoen MW; Hoque S; Witherspoon BJ; Schooley B; Sartor O; Yang YT; Yarnold PR; Knopf KB; Hrushesky WJM; Dickson M; Chen BJ; Nabhan C; Bennett CL
    Int J Cancer; 2020 May; 146(10):2829-2835. PubMed ID: 32037527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
    BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.
    Lai Y; Palazzo JP; Cristofanilli M; Hyslop T; Civan J; Avery T; Myers RE; Li B; Ye Z; Xing J; Yang H
    Breast Cancer Res Treat; 2014 Nov; 148(1):175-85. PubMed ID: 25261294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
    Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
    Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.